Central Nervous System

Clinical understanding of neurobiology is incomplete, contributing to clinical development programs in Central Nervous System (CNS) having the highest failure rates across all therapeutic areas. CNS clinical trials bring specific challenges including managing placebo response, incorporating soft endpoints, and a particular focus on reducing patient burden.

Unsurprisingly this had led to a challenging of accepted and established norms by CNS drug developers.

We support sponsors in minimising development risk and maximising probability of success through:

• Access to the latest, applied technology innovation and processes
• Working with our highly qualified and therapeutically trained staff
• Real time data quality monitoring and analysis

Services for CNS, Pain and Ageing Diseases

Our Protocol Optimisation and Clinical Development Plans service is complemented with Adaptive Design competency and regulatory approved software. Our full service study/program implementation and execution includes: 

• Laboratory and medical imaging biomarker capability
• CNS site and KOL expert network access
• (Electronic) Clinical Outcomes Assessment and digital endpoints expertise
• Access to biobanks and patient registries
• Advice on use and implementation of innovative wearable technologies

Dedicated specialist teams

All staff assigned to projects including; Project Management, Drug Development, Site Identification and Feasibility, and Medical oversight attend customised training programs. Over the past 5 years ICON have conducted phase II & III studies in a range of CNS indications. We also offer dedicated teams for rare and paediatric CNS programs.